Heparin

"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

Descriptor ID	D006493
MeSH Number(s)	D09.698.373.400
Concept/Terms	Heparin Heparin Unfractionated Heparin Heparin, Unfractionated Heparinic Acid Liquaemin Liquaemin Sodium Heparin Sodium Heparin Heparin, Sodium Heparin Sodium alpha-Heparin alpha-Heparin alpha Heparin

Below are MeSH descriptors whose meaning is more general than "Heparin".

Chemicals and Drugs [D]
Carbohydrates [D09]
Polysaccharides [D09.698]
Glycosaminoglycans [D09.698.373]
Heparin [D09.698.373.400]

Below are MeSH descriptors whose meaning is related to "Heparin".

Below are MeSH descriptors whose meaning is more specific than "Heparin".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.

Bar chart showing 139 publications over 30 distinct years, with a maximum of 10 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	4	2	6
1993	1	1	2
1994	0	4	4
1995	0	7	7
1996	0	2	2
1997	5	3	8
1998	1	2	3
1999	2	0	2
2000	0	3	3
2001	3	5	8
2002	4	2	6
2003	2	3	5
2004	3	6	9
2005	5	5	10
2006	5	3	8
2007	0	3	3
2008	2	4	6
2009	3	5	8
2010	0	2	2
2011	1	0	1
2012	0	2	2
2013	3	0	3
2014	3	2	5
2015	1	1	2
2016	2	2	4
2017	4	3	7
2018	3	1	4
2019	2	1	3
2020	0	2	2
2021	2	2	4

Below are the most recent publications written about "Heparin" by people in Profiles.

Rabon AD, Taber DJ, Uber WE, Houston BA, Meadows H. Unfractionated and Low-Molecular-Weight Heparin for Bridging Patients with Left Ventricular Assist Device: An Event-Based Analysis. ASAIO J. 2021 12 01; 67(12):1277-1283.

View in: PubMed
Maatouk B, Jaffa MA, Karam M, Fahs D, Nour-Eldine W, Hasan A, Jaffa AA, Mhanna R. Sulfated alginate/polycaprolactone double-emulsion nanoparticles for enhanced delivery of heparin-binding growth factors in wound healing applications. Colloids Surf B Biointerfaces. 2021 Dec; 208:112105.

View in: PubMed
Wiethorn EE, Harrison S, Weeda ER, Bell CM. Effectiveness and Safety of Twice- Versus Thrice-Daily Subcutaneous Heparin for Venous Thromboembolism Prophylaxis at a Large Academic Medical Center. Ann Pharmacother. 2022 05; 56(5):541-547.

View in: PubMed
Biemond BJ, Tombak A, Kilinc Y, Al-Khabori M, Abboud M, Nafea M, Inati A, Wali Y, Kristensen J, Kowalski J, Donnelly E, Ohd J. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021 May; 8(5):e334-e343.

View in: PubMed
Flores EB, Bartee MY, Bartee E. Reduced cellular binding affinity has profoundly different impacts on the spread of distinct poxviruses. PLoS One. 2020; 15(4):e0231977.

View in: PubMed
Betala J, Bae S, Langan EM, LaBerge M, Lee JS. Combinatorial therapy of sirolimus and heparin by nanocarrier inhibits restenosis after balloon angioplasty ex vivo. Nanomedicine (Lond). 2020 05; 15(12):1205-1220.

View in: PubMed
Zhu F, Piotin M, Steglich-Arnholm H, Labreuche J, Holtmannspötter M, Taschner C, Eiden S, Haussen DC, Nogueira RG, Papanagiotou P, Boutchakova M, Siddiqui AH, Lapergue B, Dorn F, Cognard C, Killer-Oberpfalzer M, Mangiafico S, Ribo M, Psychogios MN, Spiotta A, Anadani M, Labeyrie MA, Mazighi M, Biondi A, Richard S, Anxionnat R, Bracard S, Turjman F, Gory B. Periprocedural Heparin During Endovascular Treatment of Tandem Lesions in Patients with Acute Ischemic Stroke: A Propensity Score Analysis from TITAN Registry. Cardiovasc Intervent Radiol. 2019 Aug; 42(8):1160-1167.

View in: PubMed
O'Leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology. 2019 07; 157(1):34-43.e1.

View in: PubMed
Malalur P, Greenberg C, Lim MY. Limited impact of clinician education on reducing inappropriate PF4 testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2019 Feb; 47(2):287-291.

View in: PubMed
Ramu B, Cogswell RJ, Reding MT, John R, Martin CM. Plasma exchange to remove heparin-induced thrombocytopenia antibodies and the use of heparin during cardiopulmonary bypass in critically ill cardiac patients. J Heart Lung Transplant. 2018 08; 37(8):1038-1040.

View in: PubMed

People

Explore

Similar Concepts

Top Journals